Fortrea Holdings Inc. (FTRE) shares surged 7.11% in pre-market trading on Wednesday following the release of its third-quarter 2025 financial results, which exceeded analyst expectations and prompted the company to raise its full-year revenue guidance.

The clinical research organization reported Q3 revenue of $701.3 million, significantly beating the consensus estimate of $645.7 million from 8 analysts. This represents a solid increase from $674.9 million in the same quarter last year, indicating growing demand for Fortrea's services. The company's book-to-bill ratio of 1.13x for the quarter further underscores the strong market demand.

While Fortrea posted a GAAP net loss of $15.9 million, or $0.17 per share, its adjusted EBITDA of $50.7 million surpassed analyst expectations of $47 million. The company's ongoing cost-saving initiatives appear to be contributing positively to its financial performance.

In light of the strong results, Fortrea raised its 2025 revenue guidance to a range of $2,700 million to $2,750 million. The company also narrowed its 2025 adjusted EBITDA guidance to $175 million to $195 million, demonstrating confidence in its operational efficiency and market position.

Anshul Thakral, CEO of Fortrea, commented on the results, stating, "Fortrea delivered a solid performance that met expectations in the third quarter by partnering with our clients and advancing the development of potentially life-changing treatments for patients." He expressed confidence in the company's global footprint, differentiated capabilities, and therapeutic expertise to deliver on its goals.

The pre-market surge in Fortrea's stock price reflects investor optimism about the company's strong revenue growth, raised guidance, and its positioning in the competitive clinical research market. As the biotechnology and medical research sectors continue to expand, Fortrea's performance suggests it is well-positioned to capitalize on industry opportunities.